143 related articles for article (PubMed ID: 16490840)
1. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?
Chai W; Garrelds IM; de Vries R; Danser AH
Hypertension; 2006 Apr; 47(4):665-70. PubMed ID: 16490840
[TBL] [Abstract][Full Text] [Related]
2. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
4. Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts.
Yoshino T; Nagoshi T; Anzawa R; Kashiwagi Y; Ito K; Katoh D; Fujisaki M; Kayama Y; Date T; Hongo K; Yoshimura M
J Endocrinol; 2014 Aug; 222(2):289-99. PubMed ID: 24895416
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts.
Kobayashi N; Yoshida K; Nakano S; Ohno T; Honda T; Tsubokou Y; Matsuoka H
Hypertension; 2006 Apr; 47(4):671-9. PubMed ID: 16505212
[TBL] [Abstract][Full Text] [Related]
6. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
[TBL] [Abstract][Full Text] [Related]
7. Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats.
Rochetaing A; Chapon C; Marescaux L; Le Bouil A; Furber A; Kreher P
Can J Physiol Pharmacol; 2003 Sep; 81(9):864-72. PubMed ID: 14614522
[TBL] [Abstract][Full Text] [Related]
8. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response.
Fraccarollo D; Galuppo P; Schraut S; Kneitz S; van Rooijen N; Ertl G; Bauersachs J
Hypertension; 2008 Apr; 51(4):905-14. PubMed ID: 18299485
[TBL] [Abstract][Full Text] [Related]
9. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
10. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
Urabe A; Izumi T; Abe Y; Taniguchi I; Mochizuki S
Hypertens Res; 2006 Aug; 29(8):627-34. PubMed ID: 17137219
[TBL] [Abstract][Full Text] [Related]
11. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II.
Chai W; Garrelds IM; de Vries R; Batenburg WW; van Kats JP; Danser AH
Hypertension; 2005 Oct; 46(4):701-6. PubMed ID: 16144984
[TBL] [Abstract][Full Text] [Related]
12. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone preserves cardiac norepinephrine reuptake in salt-sensitive Dahl rats.
Buss SJ; Backs J; Kreusser MM; Hardt SE; Maser-Gluth C; Katus HA; Haass M
Endocrinology; 2006 May; 147(5):2526-34. PubMed ID: 16439456
[TBL] [Abstract][Full Text] [Related]
14. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Wahed MI; Watanabe K; Ma M; Yamaguchi K; Takahashi T; Tachikawa H; Kodama M; Aizawa Y
Pharmacology; 2005 Feb; 73(2):81-8. PubMed ID: 15467302
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Mihailidou AS; Loan Le TY; Mardini M; Funder JW
Hypertension; 2009 Dec; 54(6):1306-12. PubMed ID: 19841288
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
17. Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction.
Kanashiro-Takeuchi RM; Heidecker B; Lamirault G; Dharamsi JW; Hare JM
Clin Transl Sci; 2009 Apr; 2(2):134-42. PubMed ID: 20072663
[TBL] [Abstract][Full Text] [Related]
18. Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?
Chai W; Hofland J; Jansen PM; Garrelds IM; de Vries R; van den Bogaerdt AJ; Feelders RA; de Jong FH; Danser AH
J Hypertens; 2010 May; 28(5):1044-53. PubMed ID: 20179635
[TBL] [Abstract][Full Text] [Related]
19. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction.
Enomoto S; Yoshiyama M; Omura T; Matsumoto R; Kusuyama T; Kim S; Izumi Y; Akioka K; Iwao H; Takeuchi K; Yoshikawa J
Heart; 2005 Dec; 91(12):1595-600. PubMed ID: 15797934
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Mihailidou AS; Mardini M; Funder JW; Raison M
Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
